BeyondSpring
OverviewSuggest Edit
BeyondSpring (also known as Spring Pharmaceuticals) is a biopharmaceutical company. It develops immuno-oncology cancer therapies and offers a drug development pipeline which includes a variety of Plinabulin products. The company also provides a preclinical immuno-oncology pipeline that includes BPI-002, BPI-003, and BPI-004 programs.
| Type | Public | |
| Founded | 2010 | |
| HQ | New York, NY, US | Map |
| Website | beyondspringpharma.com | |
| Employee Ratings | More |
Recent NewsAll News
- BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney
- BeyondSpring to Participate in the William Blair Biotech Focus Conference
- BeyondSpring to Host R&D Day to Discuss Novel Immune Agent Plinabulin’s Development Program in Anti-cancer Indications
- BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update
Key People/Management at BeyondSpring
Lan Huang
Co-Founder, Chairman & Chief Executive Officer
Patrick Fabbio
Director
Ramon Mohanlal
EVP, Research and Development, Chief Medical Officer
Matthew Kirby
Director
Rich Daly
Chief Operating Officer
Ravindra Majeti
Director
BeyondSpring Office Locations
BeyondSpring has an office in New York
New York, NY, US (HQ)
28 Liberty St 39th Floor
BeyondSpring Financials and Metrics
BeyondSpring Revenue
| USD | |
|---|---|
Net income (FY, 2019) | (40.3m) |
EBIT (FY, 2019) | (40.3m) |
Market capitalization (28-Jul-2021) | 381.3m |
Closing stock price (28-Jul-2021) | 9.8 |
Cash (31-Dec-2019) | 35.9m |
EV | 349.3m |
BeyondSpring's current market capitalization is $381.3 m.
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 |
|---|---|---|---|---|---|---|---|---|---|
General and administrative expense | 1.0m | 2.8m | 3.3m | 728.0k | 1.4m | 1.5m | 1.6m | 2.1m | 2.5m |
R&D expense | 46.7m | 12.2m | 15.3m | 14.1m | 11.0m | 14.1m | 6.3m | 5.2m | 7.2m |
Operating expense total | 47.8m | 15.0m | 18.6m | 14.8m | 12.4m | 15.7m | 8.0m | 7.3m | 9.7m |
EBIT | (47.8m) | (15.0m) | (18.6m) | (14.8m) | (12.4m) | (15.7m) | (7.7m) | (7.3m) | (9.7m) |
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 54.6m | 49.0m | 37.7m | 18.4m | 19.4m | 12.8m | 2.0m | 674.0k | 24.7k |
Prepaid Expenses | 131.0k | 338.0k | 236.0k | 284.0k | 525.0k | 473.0k | 150.0k | 167.0k | 362.0 |
Current Assets | 55.7m | 50.8m | 43.2m | 23.3m | 24.8m | 15.2m | 3.6m | 2.0m | 30.2k |
PP&E | 88.0k | 87.0k | 126.0k | 124.0k | 116.0k | 191.0k | 263.0k | 237.0k | 217.0 |
Annual
Quarterly
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2019 | Q1, 2019 | Q2, 2019 | Q3, 2019 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 47.7m | (62.6m) | (80.1m) | (14.1m) | (26.9m) | (42.8m) | (7.8m) | (15.4m) | (25.3m) |
Depreciation and Amortization | 6.0k | 13.0k | 22.0k | 12.0k | 20.0k | 29.0k | 23.0k | 41.0k | 61.0k |
Accounts Payable | 568.0k | 1.6m | 581.0k | 1.0m | (575.0k) | (18.0k) | (620.0k) | (1.1m) | (7.6m) |
Cash From Operating Activities | (5.3m) | (10.4m) | (18.6m) | (8.9m) | (22.0m) | (31.6m) | (5.1m) | (13.1m) | (35.5m) |
| USD | FY, 2016 |
|---|---|
Financial Leverage | 1.2 x |
BeyondSpring Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Beijing Wanchun Pharmaceutical Technology Ltd. | ||
| BeyondSpring (HK) Limited | ||
| BeyondSpring LTD. | ||
| BeyondSpring Pharmaceuticals Inc. | ||
| BeyondSpring Pharmaceuticals Australia PTY | ||
| SEED | ||
| SEED Technology | ||
| Wanchun Biotechnology Limited | ||
| Wanchun Biotechnology (Shenzhen) Ltd. | ||
| Wanchunbulin |
BeyondSpring Cybersecurity Score
BeyondSpring Environment, Social & Governance (ESG) Ratings
BeyondSpring Online and Social Media Presence
146 Twitter followers
BeyondSpring has 146 Twitter Followers. The number of followers has increased 3% month over month and increased 5.4% quarter over quarter
BeyondSpring's Trends
Twitter Engagement Stats for @BeyondSpringInc
110
Tweets
8
Following
146
Followers
8
Tweets last 30 days
1.9
Avg. likes per Tweet
100%
Tweets with engagement
BeyondSpring News and Updates
July 14, 2021
BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney
NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced the appointment of Brendan Delaney to its Board of Directors, effective immediately. Mr. Del…
July 08, 2021
BeyondSpring to Participate in the William Blair Biotech Focus Conference
NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will participate in the William Blair Biotech Focus Conference being held vir…
June 17, 2021
BeyondSpring to Host R&D Day to Discuss Novel Immune Agent Plinabulin’s Development Program in Anti-cancer Indications
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the develop…
June 16, 2021
BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update
- NDA Filed by U.S. Food and Drug Administration (FDA) and given Priority Review for plinabulin plus G-CSF for the prevention of CIN. A PDUFA date of November 30, 2021 has been assigned by the FDA
June 11, 2021
BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021
NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will host a conference call to report its financial results for the first qua…
June 10, 2021
BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting
- Data further supports plinabulin’s fast onset of action and CIN prevention benefit in week 1 following chemotherapy
BeyondSpring Blogs
December 10, 2019
BeyondSpring’s Study 106 Phase 3 Superior Trial Design Combining Plinabulin with Pegfilgrastim Versus Pegfilgrastim Alone for Chemotherapy-Induced Neutropenia Presented at ASH 2019 Annual Meeting
Trial Aims to Optimize Chemotherapy by Minimizing Dose Modifications Due to Chemotherapy-Induced Neutropenia or Bone Pain NEW YORK , Dec. 10, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer
December 09, 2019
BeyondSpring’s Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin’s Mechanism of Action for CIN Accepted at American Society of Hematology’s 2019 Annual Meeting
BeyondSpring’s Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin’s Mechanism of Action for CIN Accepted at American Society of Hematology’s 2019 Annual Meeting
Content Import
Mon, 12/09/2019 - 08:01
BeyondSpring’s Abstracts on Clinical Evidence for Bone Marr…
November 11, 2019
BeyondSpring’s Single-Blinded Design (for Patients Only) of Phase 3 Study 103 (DUBLIN-3) Prevented Premature Patient Drop-Out: Data Accepted for Presentation at SITC 2019
Premature Patient Drop-Out Rate from Comparator Arm Might Contribute to Negative Trial Outcome, and was Avoided in DUBLIN-3 NEW YORK , Nov. 11, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology
November 06, 2019
BeyondSpring Appoints Gregg Russo as Senior Vice President, Human Resources
NEW YORK , Nov. 06, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has appointed Gregg Russo as Senior Vice President, Human Resources,
October 25, 2019
BeyondSpring Announces Pricing of Ordinary Shares
NEW YORK , Oct. 25, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced the pricing of its
October 24, 2019
BeyondSpring Announces Proposed Public Offering of Ordinary Shares
NEW YORK , Oct. 24, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced the launch of an
BeyondSpring Frequently Asked Questions
When was BeyondSpring founded?
BeyondSpring was founded in 2010.
Who are BeyondSpring key executives?
BeyondSpring's key executives are Lan Huang, Patrick Fabbio and Ramon Mohanlal.
How many employees does BeyondSpring have?
BeyondSpring has 61 employees.
Who are BeyondSpring competitors?
Competitors of BeyondSpring include Omeros, Athersys and Otonomy.
Where is BeyondSpring headquarters?
BeyondSpring headquarters is located at 28 Liberty St 39th Floor, New York.
Where are BeyondSpring offices?
BeyondSpring has an office in New York.
How many offices does BeyondSpring have?
BeyondSpring has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies